Overall rank by patents
#29,324
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Lumos Pharma, Inc.
USPTO PatentsView assignee record - 9 granted patents across 7 technology areas, active 2018–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
9
Total patents granted
7
CPC technology areas
12.3
Avg claims per patent
+25%
5-year filing velocity
The verdict
Lumos holds 9 US patents across 7 technology areas, rank #29,324 of 50,000 tracked assignees.
- #29,324
- of 50,000 US assignees by volume
- Top 62%
- by Innovation Score (31.4/100)
- 12.3
- avg claims per patent
- +25%
- filing velocity, last 5 yrs
Portfolio overview
Lumos Pharma, Inc. has been granted 9 US utility patents between 2018 and 2025, placing Lumos Pharma, Inc. at rank #29,324 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.3 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, Lumos Pharma, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Lumos sits between Lumasense Technologies Holdings, Inc. (9 patents, rank #29,320) and M. M. & R. Products, Inc. (9 patents, rank #29,328) - the closest US assignees by grant volume. The composite Innovation Score of 31.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 5 grants, compared with 4 in the 2015–2019 window, a +25% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Lumos Pharma, Inc.'s 12.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Lumos Pharma, Inc. against peers pursuing similar technology classes.
Who files at Lumos's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Lumasense Holdings
LumaSense Technologies Holdings, Inc.
9 patents
- Lumenium
Lumenium LLC
9 patents
- Lumentrics
Lumentrics, Inc.
9 patents
- Lumitec
Lumitec, LLC
9 patents
- Luneta
Luneta, LLC
9 patents
- M&M Sales Enterpr…
M&M Sales Enterprises Inc.
9 patents
- M Arthur Gensler…
M. Arthur Gensler, Jr. & Associates, Inc.
9 patents
- M M & R Products
M. M. & R. Products, Inc.
9 patents
- Lumos Pharma ◀
Lumos Pharma, Inc.
9 patents
What this shows Lumos holds 9 patents at rank #29,324, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Lumos
By rank, the assignees closest to #29,324 in granted patent volume.
- Lumasense Technologies Holdings, Inc. #29,320 · 9 patents
- Lumenium Llc #29,321 · 9 patents
- Lumentrics, Inc. #29,322 · 9 patents
- Lumitec, Llc #29,323 · 9 patents
- Luneta, Llc #29,325 · 9 patents
- M&M Sales Enterprises Inc. #29,326 · 9 patents
- M. Arthur Gensler, Jr. & Associates, Inc. #29,327 · 9 patents
- M. M. & R. Products, Inc. #29,328 · 9 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Lumos's primary technology class.
- The Regents Of The University Of California 1,779 in class
- L'oreal 1,250 in class
- Novartis Ag 988 in class
- The Procter & Gamble Company 985 in class
- The Board Of Regents Of The University Of Texas System 950 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 813 in class
- The Trustees Of The University Of Pennsylvania 768 in class
- Merck Sharp & Dohme Llc 760 in class
Lumos's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
31 Top 62% higher than 38% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 2 | 22.2% |
| 2019 | 2 | 22.2% |
| 2021 | 1 | 11.1% |
| 2022 | 2 | 22.2% |
| 2024 | 1 | 11.1% |
| 2025 | 1 | 11.1% |
Which technologies does Lumos Pharma, Inc. patent most?
Top 7 of 7 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Growing
Frequently Asked Questions
How many patents does Lumos Pharma, Inc. hold?
Lumos Pharma, Inc. holds 9 US granted patents filed between 2018 and 2025, spanning 7 technology areas.
What is Lumos Pharma, Inc.'s Innovation Score?
Lumos Pharma, Inc. has an Innovation Score of 31.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Lumos Pharma, Inc. focus on?
Lumos Pharma, Inc.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 9 patents. The company has filed patents in 7 CPC subclasses total.
Is Lumos Pharma, Inc.'s patent filing rate increasing or decreasing?
Lumos Pharma, Inc.'s recent filing velocity is +25% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Lumos Pharma, Inc.'s patents?
Lumos Pharma, Inc.'s patents average 12.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the Lumos Pharma, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Lumos's 9 grants land it in the top 62% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Lumos ranks #29,324 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.